(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 November 2011 (17.11.2011)

PCT

(10) International Publication Number
WO 2011/143645 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:
PCT/US2011/036572

(22) International Filing Date:
16 May 2011 (16.05.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/334,734 14 May 2010 (14.05.2010) US

(71) Applicant *(for all designated States except US)*: **OSI PHARMACEUTICALS, LLC** [US/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MULVIHILL, Mark, J.** [US/US]; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **STEINIG, Arno, G.** [DE/US]; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **CREW, Andrew, Philip** [GB/US]; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **JIN, Meizhong** [CN/US]; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **KLEINBERG, Andrew** [US/US]; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **LI, An-Hu** [US/US]; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **WANG, Jing** [US/US]; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US).

(74) Agents: **FORMAN, Frank, W.** et al.; OSI Pharmaceuticals, LLC, 1 Bioscience Park Drive, Farmingdale, NY 11735 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) Title: FUSED BICYCLIC KINASE INHIBITORS



(I)

(57) Abstract: Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

WO 2011/143645 A1